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Summary Allele imbalance on chromosome 11 loci in ovarian cancer is a frequent event, suggesting the
presence of tumour-suppressor genes for ovarian carcinogenesis on this chromosome. Ten highly polymorphic
(CA) repeat microsatellites were used to determine allele imbalance in 60 primary ovarian tumours, including
47 epithelial ovarian cancers (EOCs). Forty EOCs (85%) showed allele imbalance at one or more loci, and in
39 of these (83%) the data suggested subchromosomal deletions: eight of I lp only; six of 1 lq only; and 25 of
both llp and llq. Three consensus regions of deletion were indicated at llpl5.5-pl5.3, llql2-q22 and
l1q23.3-q24.1. Allele imbalance at the llq subtelomeric region (DllS912) correlated significantly with
adverse survival, while imbalance at 1 lqI4.3 and retention of heterozygosity at 1 1q22 (close to the site of the
progesterone receptor gene) were associated with favourable clinicopathological features. The findings allow
development of a preliminary model for the molecular evolution of epithelial ovarian cancer.
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Epithelial ovarian cancer is the main cause of death from
gynaecological cancer in British women, primarily because of
its late presentation, which carries a poor prognosis despite
available treatment modalities. Interest is focusing on the
molecular basis of ovarian cancer in order to uncover new
and hopefully effective management strategies.
Strong circumstantial evidence for the location of tumour-
suppressor genes (TSGs) can be obtained by observed allele
imbalance (loss of heterozygosity, LOH) in tumour DNA
compared with a matched constitutional DNA specimen at
defined chromosomal loci (Ponder, 1988). Minimum consen-
sus regions of allele imbalance may lead to isolation and
cloning of these 'deleted' genes, and LOH studies in many
tumour types have suggested putative TSGs located on
chromosome 11.
In ovarian cancer, cytogenetic analysis has demonstrated
partial deletions of chromosome 11 affecting both the long
and short arms (Bello and Rey 1990; Pejovic et al., 1992;
Jenkins et al., 1993). Frequent LOH has been demonstrated
at 1lpl5 (Lee et al., 1989; Ehlen and Dubeau, 1990; Eccles et
al., 1992a; Gallion et al., 1992; Vandamme et al., 1992; Viel
et al., 1992; Kiechleschwarz et al., 1993), although not all
studies have confirmed this high level of loss (Sato et al.,
1991; Zheng et al., 1991; Yangfeng et al., 1992). A proximal
locus at lpl3 (site of WT1) exhibits lower rates of LOH in
ovarian cancer (Call et al., 1990; Vandamme et al., 1992; Viel
et al., 1992; Bruening et al., 1993). A minority of these
studies have proposed a correlation of I lp LOH with poorly
differentiated (Zheng et al., 1991; Kiechleschwarz et al., 1993)
and more advanced (Viel et al., 1992) tumours. Molecular
studies of the proximal 1 lq region have shown low rates of
both LOH and amplification of the 1 1q13 amplicon in
ovarian cancer (Lee et al., 1989; Li et al., 1991; Sato et al.,
1991; Viel et al., 1992; Foulkes et al., 1993). In contrast, the
only study that has looked specifically at the subtelomeric
region of 1llq (Foulkes et al., 1993) recorded a high rate of
allele imbalance at 1 lq23.3-qter in a small sample of
tumours. The advent of highly polymorphic, well-mapped,
microsatellites distributed evenly throughout the genome
(Weissenbach et al., 1992; Gyapay et al., 1994) and amenable
to polymerase chain reaction (PCR) amplification has
allowed rapid LOH analysis using small amounts of DNA
(Futreal et al., 1992), which can be derived, if necessary,
from archival material.
We have used 10 (CA)" polymorphic microsatellites to
determine allele imbalance on chromosome 11 in ovarian
tumours removed from 60 women [47 epithelial ovarian
cancers (EOCs), five borderline malignancies, three
adenofibromas, two mixed mesodermal tumours, two
granulosa cell tumours and one teratoma]. The data have
been analysed in relation to clinicopathological findings.
Materials and methods
Clinical specimens
Fresh primary ovarian tumour tissue from 60 patients was
transferred directly to dry ice or liquid nitrogen and stored at
- 70C. The normal tissue for comparison was blood in 39
patients and normal regions from formalin-fixed blocks in 21
patients. FIGO staging, histopathology and differentiation
state were determined and reviewed in a standardised fashion
at a multidisciplinary combined gynaecological oncology
clinic. Treatment was in accordance with standard protocols,
which consisted of the best possible surgical debulking
followed by adjuvant/palliative chemotherapy. Minimum
follow-up from diagnosis is 24 months, with median follow-
up (by reverse Kaplan-Meier method) of 47 months. All
deaths that have occurred have been due to ovarian cancer.
Patient characteristics are outlined in Table I.
DNA extraction
DNA from fresh-frozen tissue and blood was extracted by a
standard technique as previously described (Eccles et al.,
1990). DNA extraction from fixed specimens was performed
by cutting 3 x 10 ltm sections, dewaxing in xylene, washing in
100% ethanol and desiccating the specimen. Proteinase K
(200 jig ml-') digestion was performed overnight at 37°C fol-
lowed by heat inactivation. Debris was removed by centri-
fugation, providing a preparation containing adequate DNA
template for PCR.
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Table I Clinicopathological characteristics of the 60 patients with
ovarian tumours
Number of patients
Ovarian adenocarcinoma
Histology
Serous
Endometrioid
Mucinous
Clear cell
Differentiation
Well
Moderate
Poor
Not known
Stage
I/II
III/IV
Not known
Surgical treatment
Completely debulked
Incompletely debulked
Not known
Chemotherapy
Chlorambucil
Adjuvant
Palliative
Cis-platinum
Adjuvant
Palliative
Carboplatinum
Palliative
None
Borderline malignant potential
Mixed mesodermal tumour
Granulosa tumour
60
47
25
14
5
3
3
14
25
5
16
29
2
32
15
2
3
6
11
8
2
13
5
2
2
Teratoma 1
Benign adenofibroma 3
Oligonucleotide primers
Primers were selected on the basis of recently generated
microsatellite index maps for locus, informativeness and
spacing. Table II shows these primers and associated inform-
ation. A high-resolution radiation hybrid map allowed reas-
onable estimates of physical distance separating these
markers (Figure 1) (James et al., 1994).
Polymerase chain reaction andpolymorphic microsatellite
detection
PCR was performed under conditions specified in the original
papers. A 10 ,l volume of the PCR reaction product was
loaded onto 8% denaturing polyacrylamide gel, separated by
electrophoresis, passively transferred to Hybond nylon and
probed with a 32P end-labelled poly(CA) probe as previously
described (Cohen et al., 1992). Two observers visually
analysed the autoradiographs and recorded allele imbalance
when there was a clear reduction in the intensity of one allele
in tumour DNA.
Statistical analysis
The two-tailed Fisher exact test was used. Since numerous
analyses were performed, significance was set at P = 0.01, but
we have included trends towards significance in the region of
0.07> P>0.01 where they have supported or suggested
biological hypotheses. Kaplan-Meier curves and log-rank
analysis were performed (ICRF ICNET PDPLOT actuarial
survival program, W Gregory) to determine LOH-survival
relationships. Multivariate analysis was not performed
because of the small sample number.
Table II Polymorphic chromosome 11 microsatellite markers used in
this study: identity and location
Locus Location Name Referencesa
Dl lS922 lplIS.5 AFM217yblO 1,2
D1 S569 1 pl5.3 cCIII434 2,3
D1lS929 llpI4.1 AFM234xc3 1,2
D1 S935 lipl3 AFM254zb9 1,2
DlIS905 lp13- 12 AFM1O5xblO 1,2
Dl1S873 1 qI4.3 Mfdl27 GDB ID no. 32638
DI IS35 1lq22 Phage2-22 2,4
DlIS897 llq23.1 Mfd231 GDB ID no. 34742
DI lS925 1 q23.3 AFM220yb6 1,2
D1I S912 1 q24.1 AFMI57xh6 1,2
al, Weissenbach et al. (1992), Gyapay et al. (1994), Couillin et al.
(1994). 2, Litt et al. (1993). 3, Phromchotikul et al. (1992). 4, Litt et al.
(1990). GDB, genome database.
Results
Molecular analysis
Clinicopathological characteristics of the patient cohort are
outlined in Table I. Table III shows the allele imbalance
results for all markers and subgroups in this study.
Eighty-seven per cent of all ovarian tumours (52/60) and
85% of EOCs (adenocarcinomas excluding borderline malig-
nancies) (40/47) had evidence of LOH involving at least one
locus on chromosome 11. Only one EOC had LOH at all
informative loci, and seven EOCs (15%) had no detectable
LOH. Examples of allele loss for each of the markers are
shown in Figure 1.
Analysis of consensus regions of allele imbalance in ovararian
EOCs Figure 2 is a graphic representation of the data from
Table III showing that serous, poorly differentiated and
advanced stage EOCs have particularly high levels of LOH at
both the Ilp and 1 lq subtelomeric regions. Conversely,
EOCs which are early stage or moderately/well differentiated
appear to have high levels of LOH at the 1 lql4.3-q22
region.
Figure 3 shows those tumours that have partial losses on
chromosome 11. Deletions are shown in shaded bars and are
limited by the next heterozygous locus. In cases where a
locus with allele loss is separated by an uninformative locus
from a locus that remains heterozygous, that uninformative
locus is included within the shaded bars as part of the
deletion (since this region could be deleted). Eight tumours
had only lIp loss, six tumours had only llq loss and 25
tumours had partial loss of both arms. This type of analysis
suggests three shortest regions ofoverlap (SROs) correspond-
ing to three consensus regions of deletion/allele imbalance at
llpl5.5-15.3, 1lq23.3-qter and llpl2-q22.
Ilp loss of heterozygosity LOH was observed for at least
one short arm locus in 77% (46/60) of all informative
tumours, including 72% of EOCs (34/47).
For all ovarian tumours, high levels of LOH (>40%) were
found for three loci (see Table III): DllS922 at llplS.5 in
24/47 informative tumours (51%) and 16/36 EOCs (44%);
Dl 1S569 at lIplS.3 in 23/43 informative tumours (54%) and
14/30 EOCs (47%); and at DIIS905 at llpl3-12 in 21/45
informative tumours (47%) and 15/33 EOCs (45%). When
considering only those tumours that were informative at both
loci telomeric to IlplS.3 (Dl 1S569 and Dl lS922), the rate of
lIp subtelomeric LOH was 16/24 (67%).
The lowest frequencies of allele loss on lp were detected
at DIIS929 (lHpl4.1), with only 28% LOH in ovarian
tumours and 24% LOH in EOCs.
Jlq loss of heterozygosity llq LOH was observed for at
least one locus in 65% (39/60) of all informative tumours,
including 66% of EOCs (31/47).Chromosome 11 allele imbalance in ovariantunmums
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Figure 1 Idiogram of chromosome with examples of allele imbalance. Constitutive DNA (left lane) and tumour DNA (right
lane) for each microsatellite locus are shown with approximate distances between loci.
For all ovarian tumours, high levels of LOH were seen in
three loci (see Table III): DllS873 at Iq14.3 in 11/25 infor-
mative tumours (44%) and 9/22 EOCs (41%); Dl1S925 at
1 lq23.3 in 24/45 informative tumours (53%) and 18/33 EOCs
(54%); and Dl1lS912 at 1lq24.1 in 23/49 informative
tumours (47%) and 18/37 EOCs (49%).
When considering only those EOCs that were informative
at both loci telomeric to Iq23.3 (Dl 1S925 and Dl 1S912),
the LOH rate was 18/27 (67%).
The lowest frequencies of allele loss were detected at
Dl 1S897 (1 1q23.1), with only 32% LOH in ovarian tumours
and 28% LOH in EOCs.
Allele imbalance in other ovarian tumour types The non-
EOC tumour numbers were too small for statistically valid
conclusions. We considered benign and borderline (low
maligant potential, LMP) tumours together. Only 1/8 benign
or borderline tumours had LOH at DllS569 (llpl5.3) and
1/7 had loss at DIIS912 (1lq24.1). However, 3/5 benign or
borderline tumours had LOH at DllS922 (llplS.5). Both
the mixed mesodermal tumours had LOH at both llpl5.5-
p15.3 and Iq23-qter. One granulosa cell tumour had LOH
at all loci on lIp, suggesting whole arm loss. The ovarian
teratoma in our series was hemizygous at all nine informative
loci, and this is compatible with the usual description of
these tumours as being parthenogenetic.
Microsatellite instability Microsatellite instability (MSI)
(Aaltonen et al., 1993; Thibodeau et al., 1993) was noted in
only 6.4% of EOCs (3/47). Both granulosa cell tumours had
evidence of MSI, and one of these tumours had evidence of
instability at three loci. There were no cases of MSI in five
borderline, three benign and two mixed mesodermal
tumours.
Statistical analysis
Fisher's exact test was used to analyse the relationship for
allele imbalance between specific loci and also the relation-
ship between imbalance for specific loci and clinicopatho-
logical parameters for EOCs.
Relationship of allele imbalance between different loci The
three regions of deletion ctetermined from Figure 3 were
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analysed for significant relationships. No relationship was
noted between LOH at the 1lip subtelomeric region
(DIIS922 and DIIS569 at llpl5.5-15.3) and at the llq
subtelomeric region (Dl 1S925 and Dl S912 at
Iq23.3-24.1) (P = 0.5). Similarly, no relationship was seen
between LOH at llpl2-ql4.3 (D1IS905 and DIIS873) and
the lIp subtelomere (P = 1.0). However, a significant rela-
tionship exists for LOH at the llpl2-ql4.3 region and the
llq subtelomeric region (P=0.0025), suggesting that losses
at these two regions co-segregrate. Alternatively, they could
be part of a single deletion group, although Figure 3 suggests
that this is not the case.
Fisher's exact test was used to test allele imbalance
between all possible combinations of loci (Figure 4). For loci
adjacent or close to each other, significant and borderline
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Figure 2 Graphic representation of allele imbalance rates from
Table III for various clinicopathological parameters. (a) =,
Serous; , endometrioid; *, mucinous. (b) 0, Moderately/
well differentiated; *, poorly differentiated. (c) 0, Early FIGO;
*, advanced FIGO.
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findings are likely to reflect association simply as part of Relationship between allele imbalance and clinicopathological
substantial subchromosome deletions which may include a parameters Table IV shows Fisher's test P-values with
tumour-suppressor gene. For loci distant from each other, significance trends for clinicopathological parameters at the
DlI S912/DllS935 LOH showed a significant statistical rela- loci tested.
tionship (P = 0.0073) and the relationship for Dl1IS935/
Dl 1S922 was of borderline signifiance (P = 0.046), suggesting Allele imbalance and histology No significant difference was
the possibility that these loci harbour genes which may be seen at any locus, comparing serous EOCs with other histo-
inactivated cooperatively. logies. However, of nine informative endometrioid tumours,
Tumour N. D11S922 D11S569 D11S929 D11S935 D11S905 D11S873 D11S35 D11S897 D11S925 D11S912
1lpl5.5 11pl5.3 11pl4.1 11p13 llpl3-12 11q14.3 11q22 11q23.1 11q23.3 1lq24.1
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Figure 3 Grey horizontal bars represent the extent of subchromosomal deletions in EOCs. Black vertical lines represent
approximate positions of the shortest regions of overlap (SROs); three such regions are apparent. L = constitutively heterozygous
with allele loss/imbalance in tumour DNA. U = constitutively homozygous and therefore uninformative at that locus.k Chromosome 11 allele imbalance in ovarian tumours
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Loci tested P-value Distance D11S922 D11S929 D11S905 D11S35
between loci 11p15.5 11p14.1 11p13-12 11q22
(Mbp) D11S569 D11S935 D11S873
11p15.3 11p13 11q14.3
D11S905 vs. D11S935 0.0015
DllS912 vs. DllS935 0.0073
D11S912 vs. D11S897 0.0088
D11S905 vs. DllS929 0.0121
DllS935 vs. DllS929 0.013
D11S897 vs. DllS873 0.0152
D11S925 vs. D11S35 0.0185
D11S912 vs. DllS929 0.0189
D11S935 vs. DllS922 0.046
D1lS912 vs. DllS925 0.057
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Figure 4 Fisher's exact test analysis of co-loss between markers on chromosome 11.
Table IV Fisher's exact test comparing ovarian adenocarcinoma
clinicopathological groups at chromosome 11 loci
Marker LOH Segregation parameter P-value
Dl 1S912 Dead (vs alive) patients with 24 months 0.0067
minimum follow-up
DI lS912 Dead (vs alive) patients at 24 months 0.067
DllS912 Late (vs early) FIGO stage tumours 0.035
DI lS35 Non-endometrioid (vs endometrioid) 0.04
histology
DI lS873 Well (vs poorly) differentiated tumours 0.07
DI 1S912 Non-debulked (vs debulked) tumours 0.075
post surgery
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Figure 5 Kaplan Meier survival curve with log-rank analysi
for subtelomeric Ilq allele imbalance status at presentation.
none had LOH at DlIS35, and comparing this group with
other histologies a trend towards significance was observed
for LOH of this marker with non-endometrioid histology
(P = 0.04).
Allele imbalance and FIGO stage The only observed trend
towards significance was for the association of LOH at
Dl S912 with FIGO stage III/IV EOCs (P = 0.035).
Allele imbalance and differentiation grade The only apparent
trend towards significance was between Dl S873 LOH and
well/moderately differentiated tumours (P = 0.07).
Survival Dl lS912 loss of heterozygosity at 1 lq23.3-24.1 in
primary tumours at diagnosis was associated with adverse
Figure 6 Kaplan-Meier survival curve with log-rank analysis
for Dl 1S912 (1 1q24.1) allele imbalance status at presentation.
survival of patients with adenocarcinoma (P = 0.0067) with
minimum follow-up of 24 months.
Kaplan-Meier survival analysis Telomeric 1 lq LOH
(Dl 1S925 and DllS912) was significantly associated with
adverse survival for patients with ovarian adenocarcinoma
(Figure 5), and significance was increased when Dl S912
LOH was considered alone (Figure 6). Actuarial survival of
those without LOH shows 70% survival at 4 years vs. 20%
for patients who had lost a Dl S912 allele in their primary
is tumour at diagnosis.
Discussion
With a panel of ten highly informative, well-distributed,
accurately mapped microsatellite polymorphisms (MSPs),
significant levels of chromosome 11 allele imbalance were
detected in our population of 60 ovarian tumours. Although
the term allele imbalance is used interchangeably with LOH
in this paper, we have opted to use this term rather than
LOH since imbalance can also be a consequence of allele-
specific amplification and need not necessarily imply deletion
of a region of DNA. Furthermore, amplification of a region
of DNA is not mutually exclusive with loss of function at a
tumour-suppressor locus; loss of a chromosome or sub-
chromosomal region may occur with reduplication of the
other allele/chromosome, and amplification of a region of
DNA is not necessarily associated with gain of function if
accompanying inactivating mutations are involved.
~_s
Time (years)
4 O%t% lIn contrast to findings with chromosome 17 (Steel et al.,
1994), in which whole homologue or whole arm loss is
common, interstitial and small terminal deletions are in fact
more common in chromosome 11 in this same group of
ovarian tumours. A highly significant association between
allele imbalance on 17p and 17q in this material has been
observed previously (Fisher's exact test, P = 0.0007; data not
presented). No such association is observed for imbalance on
Ilp and 1lq (P = 0.65) as a whole, and this argues for
caution in the interpretation of allelotyping data that utilise
only one or two loci per chromosome arm where no previous
biological hypothesis associates that chromosome arm with
involvement in neoplasia.
However, relationships for allele imbalance between distant
chromosome 11 loci do occur; not only between adjacent
sites (which are likely to reflect larger deletions). Significant
associations do occur between two distant loci while inter-
vening loci are excluded from the relationship, as shown for
example by D1IS912/Dl1S935 and D1IS935/Dl1S922 (at
borderline significance). These pairs of loci may harbour
genes which are cooperatively inactivated as part of a multi-
step process. Consensus analysis of those EOCs with partial
deletion suggests at least three distinct regions of allele im-
balance, at llplS.5-pl5.3, llq23.3-24.1 and llpl2-ql4.3.
In contrast to previous reports (Zheng et al., 1991; Kiech-
leschwarz et al., 1993), we found no significant association
between differentiation grade and allele imbalance at the
llpl5 region (despite 67% LOH) in our sample of EOCs,
and this may reflect the lack of uniformity in ovarian cancer
grading methodology; nor could we confirm an association
between llpl5 LOH and advanced stage disease (Viel et al.,
1992), although there appeared to be a non-significant trend
for both these parameters (Figure 2). Dl lS922 LOH
(1lpl 5.5) did correlate at a borderline level of significance
(P=0.046) with LOH at Dl S935. (Significant LOH rates
have been detected in several studies at 11p13, near the site
of WTI, although direct analysis of the WT1 locus suggests
that it is not the gene involved; Bruening et al., 1993; Viel et
al., 1994.) There was also evidence of significant LOH at
Dl S922 in benign and borderline tumours. With this high
level of loss in EOCs, and without significant correlations
with advanced disease/poor prognosis subgroups, the likeli-
hood is that an 18.6 Mb interval within IlplS houses a gene
involved at an early stage in ovarian carcinogenesis, occur-
ring as part of the development of benign and borderline
tumours and also detectable at roughly similar rates in
adenocarcinoma. Allele loss at Dl1IS569 (1lplS.3) is low
(12.5%) in benign and borderline tumours, but is much
higher in carcinomas, and there is no difference in LOH rate
Chromosome 11 allele imbalance in ovarian tumours
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between early and advanced FIGO stage adenocarcinomas.
This raises the possibility of a second locus at lIp15.3 which
is inactivated as part of the development of frank adenocar-
cinoma (albeit at an early stage of adenocarcinoma develop-
ment).
We have confirmed and extended (in both numbers and
chromosomal position) the recent finding of extensive allele
loss distal to 1Iq23.3 (Foulkes et al., 1993), with 67% of
EOCs exhibiting LOH at llq23.3-24.1 in our sample. Our
proximal marker (Dl1S925) in this region maps about
1.2 Mb telomeric to the most distal marker in the study of
Foulkes et al. Loss of heterozygosity at the distal MSP
(Dl S912) at 1 1q24.1 is significantly associated with adverse
survival and advanced stage, although the latter P-value, at
0.035, is borderline.
No borderline tumours exhibited allele imbalance at
Dl lS912. Allele imbalance at the subtelomeric region at
Dl 1S912 showed significant correlation with Dl lS897
(l1q23.1) and DllS935 (llpl3 in the region of WTI). These
findings suggest that a TSG acting primarily as a 'progres-
sion suppressor' may be located at llq23.3-24.1 (or telo-
meric), and that its inactivation may be a significant late
event in the pathogenesis of epithelial ovarian cancer.
The llpl2-ql4.3 region (which is a large region contain-
ing the centromeric half of llq), although exhibiting high
levels of loss, does not appear to segregate significantly with
any particular parameter, although there is a non-significant
trend towares LOH in association with better prognosis
tumours. Allele imbalance in this region does, however,
segregate significantly with imbalance ofthe 1 lq subtelomeric
region. Dl S873 LOH at 1lql4-q22 seems to correlate with
favourable clinicopathological parameters: higher LOH rates
are observed in those with mucinous histology, early FIGO
stage and well/moderately differentiated tumours. Higher
rates of allele loss at DlIS873 are seen in those patients
remaining alive (also seen at the neighbouring locus,
Dl S905 at 11p13-12). These findings suggest the possibility
that some well-differentiated, early FIGO stage carcinomas
may belong to a genetically distinct subcategory of EOC
rather than being simply precursors of aggressive late-stage
disease (Figure 7), and that allele loss in the 1 Ip12-q22
region may confer changes incompatible with rapid progres-
sion of the disease, e.g. deletion of an oncogene locus essen-
tial for tumour progression. It is possible that LOH detected
in this region could reflect amplification of the 1 1q13 region
similar to that observed in breast cancer (Karlseder et al.,
1994), and we have not ruled out this possibility in the
present study, although previous studies of this region in
ovarian cancer (Foulkes et al., 1993) suggest that
Dn over
frame
11p15 and 11q24 LOH
Rapid evolution
Figure 7 Hypothesis for chromosome 11 involvement in ovarian carcinogenesis. For abbreviations, see text.Chromosome 11 allele imbalance in ovarian tumours
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amplification occurs infrequently. However, the explanation
for our findings of better prognosis associated with allele loss
at this locus remains obscure and requires further work.
The absence of LOH at Dl S873 and Dl S35 specifically
in endometrioid adenocarcinoma is of considerable interest,
though the finding approached statistical significance only
for the latter MSP (P = 0.04). Dl 1S35 lies about 160 kb from
the site of the progesterone receptor (PgR) gene. At least six
studies have reported that endometrioid tumours contain
PgR levels that are elevated relative to other histological
types (Slotman and Rao, 1988). Furthermore, there is evi-
dence that, in breast cancer, gene dosage, although secondary
to regulatory change, plays a significant role in determining
hormone receptor levels: tumours that are cytogenetically
6q-/1 lq- have half as many oestrogen receptors (ER) and
PgRs as tumours without losses on 6q or 1lq (Magdelenat et
al., 1994). We would therefore speculate that there may be a
role for the PgR gene in the regulation of histological sub-
types of ovarian cancer, and possibly that its structural dis-
ruption contributes to the generation of adverse histological
and prognostic subtypes at a relatively early stage in the
development of ovarian cancer.
The findings in this study extend the previous observations
of distinctive patterns of aneusomy or molecular aberrations
in ovarian cancers belonging to different clinicopathological
subgroups. They do not imply that LOH at each of the
defined regions of chromosome 11 represents independent
prognostic factors, although 1 lq subtelomere imbalance
should perhaps be subjected to a large prospective study.
Of more immediate relevance is the application of the
observed correlations synthesis of a multistep model of
ovarian carcinogenesis (Figure 7). In this model, there is not
only multistep, but also multipath, progression of ovarian
cancer, postulating, for example, the involvement of q14.3-
q22 imbalance ;in a biologically distinct subpopulation of
early EOC.
Extensive chromosome 17 microsatellite and restriction
fragment length polymorphism (RFLP) analysis of this same
cohort of patients has been performed in our laboratory
(Eccles et al., 1992b; Steel et al., 1994), and we are currently
extending our analysis to correlations between regions of
LOH on chromosomes 11 and 17 and their relationship to
clinicopathological parameters. In addition, more detailed
mapping of LOH within the llq23.3-qter region to better
define the imbalance peak is in progress. This will also
determine if there are regions telomeric to llq24 with low
rates of LOH and address the possibility that these observed
losses are simply due to non-specific telomeric high-frequency
breakages as a consequence of neoplasia rather than putative
tumour-suppressor genes at these sites.
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